Refine
Document Type
- Article (5)
Has Fulltext
- yes (5)
Is part of the Bibliography
- no (5)
Keywords
- Active middle ear implants (1)
- Auditory system (1)
- Bone conduction devices (1)
- Brain tumor (1)
- Consensus statement (1)
- EWSR1 (1)
- Gene fusion (1)
- Glioblastoma (1)
- Health policy (1)
- MGMT (1)
Institute
- Medizin (3)
Viele militärische Übungsplätze in Deutschland verfügen über ökologisch äußerst wertvolle Bereiche. Die Gründe dafür sind mannigfaltig (vgl. Högel; Lange 1992) Dort, wo eine Nutzung durch die Streitkräfte fortbesteht, soll durch Benutzungs- und Bodenbedeckungspläne die ökologische Werterhaltung festgeschrieben werden (Richtlinie 1992). In den Fällen, wo Flächen aus der militärischen Nutzung entlassen werden, entstehen Zielkonflikte durch unterschiedlichste Ansprüche (Högel; Lange 1992). Die Naturschutzbehörden müssen in diesem Falle Vorhaben zum Erhalt ökologisch wertvoller Flächen fachlich exakt begründen können. Besonders schwierig ist das bei Gebieten, die durch die sowjetischen Streitkräfte genutzt wurden. Über die ökologische Ausstattung dieser Standort- oder Truppenübungsplätze ist bislang kaum etwas bekannt, da 40 Jahre lang keine Daten erhoben werden konnten.
Am 18.4.2012 fand in Zusammenarbeit mit der Hochschule Anhalt in Bernburg das 1. Symposium der Regionalgruppe Sachsen-Anhalt des Bundesverbandes Beruflicher Naturschutz e. V. (BBN) statt, zu dem ca. 70 Vertreter aus Planungsbüros, Verwaltungen sowie den Hochschuleinrichtungen Sachsen-Anhalts kamen. Hierbei sollte der fachliche Austausch zwischen Wissenschaft, Praxis und Verwaltung gestärkt und zukünftig eine stärkere Vernetzung angestrebt werden.
Nowadays, several options are available to treat patients with conductive or mixed hearing loss. Whenever surgical intervention is not possible or contra-indicated, and amplification by a conventional hearing device (e.g., behind-the-ear device) is not feasible, then implantable hearing devices are an indispensable next option. Implantable bone-conduction devices and middle-ear implants have advantages but also limitations concerning complexity/invasiveness of the surgery, medical complications, and effectiveness. To counsel the patient, the clinician should have a good overview of the options with regard to safety and reliability as well as unequivocal technical performance data. The present consensus document is the outcome of an extensive iterative process including ENT specialists, audiologists, health-policy scientists, and representatives/technicians of the main companies in this field. This document should provide a first framework for procedures and technical characterization to enhance effective communication between these stakeholders, improving health care.
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.
Purpose: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy.
Methods: The impact of obesity (BMI ≥ 30 kg/m2) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables.
Results: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm.
Conclusion: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.